The Lancet Respiratory Medicine November 01, 2019

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

Richard T Davey Jr, Eduardo Fernández-Cruz, Norman Markowitz, et al.

Bottom Line

The FLU-IVIG trial demonstrated that adding a single dose of anti-influenza hyperimmune intravenous immunoglobulin to standard care did not improve overall clinical outcomes in adults hospitalized with severe influenza, though it generated a hypothesis for potential benefit in influenza B.

Key Findings

1. Overall, the addition of hIVIG to standard care did not demonstrate a significant clinical improvement over placebo on the day 7 ordinal scale (OR 1.25; 95% CI 0.79-1.97, p=0.33).

2. In a prespecified subgroup analysis, there was no evidence of clinical benefit in patients infected with influenza A (OR 0.94; 95% CI 0.55-1.59).

3. Patients infected with influenza B who received hIVIG had significantly better clinical outcomes at day 7 compared to placebo (OR 3.19; 95% CI 1.21-8.42; interaction p=0.023).

4. Safety profiles were similar between the two groups; the composite safety outcome of death, serious adverse events, or grade 3/4 adverse events occurred in 30% of patients in both the hIVIG group (47/156) and the placebo group (45/152) through 28 days of follow-up.

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

313

Patients

Duration

28 days

Median

Setting

Multicenter, multinational

Population Adults (≥18 years of age) admitted to the hospital with laboratory-confirmed influenza A or B infection.

Intervention A single 500-mL intravenous infusion of high-titer anti-influenza hyperimmune intravenous immunoglobulin (hIVIG) at 0.25 g/kg (up to a maximum of 24.75 g) plus standard antiviral care.

Comparator A single 500-mL intravenous infusion of saline placebo plus standard antiviral care.

Outcome Clinical status at day 7, measured on a 6-category ordinal scale ranging from death (worst) to resumption of normal activities after discharge (best).

Study Limitations

• The study was insufficiently powered to definitively establish the efficacy of hIVIG in the influenza B subgroup, making this finding hypothesis-generating rather than conclusive.

• The administration of hIVIG occurred post-hospitalization, which may represent a point in the disease course where the inflammatory cascade is too advanced for targeted antibody therapy to significantly alter clinical outcomes for influenza A.

• Differences between the historical viral strains used to manufacture the hIVIG and the actual circulating seasonal strains could have resulted in variable neutralizing efficacy.

• The 6-category ordinal scale, while standard for respiratory viral trials, may lack the sensitivity to detect subtle but clinically meaningful differences in patient recovery trajectories.

Clinical Significance

The FLU-IVIG trial provided rigorous evidence against the routine use of hyperimmune intravenous immunoglobulin for adults hospitalized with severe influenza A, challenging the historical reliance on passive immunotherapy for late-stage respiratory viral infections. However, the unexpected, statistically significant benefit observed in patients with influenza B highlighted that virus-specific factors—such as differences in antigenic drift and Fc-receptor-mediated antibody-dependent cellular cytotoxicity (ADCC)—may dictate the success of passive antibody therapies. This critical methodological insight has shifted subsequent research toward early administration protocols and the development of highly specific monoclonal antibodies rather than broad hyperimmune globulins.

Historical Context

Passive immunotherapy, including convalescent plasma and hyperimmune globulins, has been utilized during respiratory pandemics since 1918 and was widely deployed during the 2009 H1N1 influenza pandemic based primarily on observational data. Despite anecdotal successes, rigorous, large-scale, double-blind randomized controlled trials were lacking. The INSIGHT 006 (FLU-IVIG) trial was conceived by the NIH and an international consortium to definitively answer whether high-titer hyperimmune globulin improves outcomes in severe seasonal influenza. Its failure to show a benefit for influenza A predated and paralleled the later struggles of convalescent plasma therapy during the COVID-19 pandemic, collectively reshaping the modern paradigm of antibody-based therapeutics for acute severe respiratory viruses.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the fundamental mechanism of action behind hyperimmune intravenous immunoglobulin (hIVIG), and why was it hypothesized to help patients with severe influenza?

Key Response

Students need to understand the concept of passive immunity. hIVIG provides pre-formed, high-titer neutralizing antibodies against specific pathogens (like influenza hemagglutinin), theoretically blocking viral entry into host cells, enhancing opsonization, and offering immediate immunity compared to the delayed response of active vaccination.

Resident

Given the negative overall clinical results of the FLU-IVIG trial, what remains the established standard of care for the medical management of an adult hospitalized with severe influenza?

Key Response

Residents must know standard management. Despite this trial's investigation of adjunctive hIVIG, the standard of care remains early initiation of neuraminidase inhibitors (e.g., oseltamivir), supportive care for ARDS and respiratory failure, and empiric treatment of secondary bacterial pneumonias if suspected.

Fellow

The trial noted a hypothesis-generating potential benefit for patients with influenza B. Mechanistically and epidemiologically, how do influenza A and B differ, and could these differences plausibly explain a differential response to hIVIG?

Key Response

Fellows should integrate advanced virology with clinical outcomes. Influenza B undergoes antigenic drift but not shift, potentially allowing hIVIG donor pools to have higher, more cross-reactive, and more durable neutralizing antibody titers against circulating B strains compared to the rapidly mutating and highly diverse A strains.

Attending

When evaluating patients with severe influenza presenting with ARDS, how does the failure of hIVIG in this trial reshape our understanding of the disease's late-stage pathophysiology and the ideal timing of therapeutic interventions?

Key Response

Attendings must contextualize trial failures into disease models. The failure of a viral-neutralizing agent in established severe illness suggests that late-stage severe influenza is driven more by profound host inflammatory responses (cytokine storm, diffuse alveolar damage) than by ongoing viral replication, emphasizing that therapies targeting the virus must be given very early to alter the clinical trajectory.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The trial authors highlight a potential benefit in the influenza B subgroup despite a negative primary outcome for the overall cohort. From a statistical perspective, what are the primary hazards of emphasizing subgroup findings in a negative trial, and how would you design a follow-up study to rigorously test this hypothesis?

Key Response

PhDs focus on methodology. Post-hoc or secondary subgroup analyses in a trial with a negative primary outcome are highly susceptible to Type I errors (false positives) due to multiple testing and smaller sample sizes. A follow-up requires a specifically powered, prospective RCT solely enrolling influenza B patients with a predefined primary clinical endpoint.

Journal Editor

As an editor evaluating this manuscript, how do you weigh the importance of publishing a 'negative' clinical trial in a high-impact journal, and what critical methodological caveats must the authors explicitly state regarding their influenza B subgroup findings to prevent misinterpretation?

Key Response

Editors care about publication bias and accurate reporting. Publishing rigorous negative trials is crucial to prevent publication bias and protect patients from ineffective off-label therapies. The editor must ensure authors heavily caveat the influenza B finding as strictly hypothesis-generating, avoiding causal language that might prompt inappropriate clinical uptake before confirmatory trials are conducted.

Guideline Committee

Based on the findings of the FLU-IVIG trial, how should current infectious disease guidelines (such as IDSA) update their recommendations regarding the use of adjunctive passive immunotherapy for severe seasonal influenza?

Key Response

Guideline committees synthesize evidence into practice rules. Current IDSA guidelines do not recommend routine use of IVIG or convalescent plasma for influenza. This high-quality, double-blind RCT provides strong evidence to explicitly recommend against the routine clinical use of hIVIG in severe influenza A or B outside of a clinical trial, solidifying current standard-of-care antiviral recommendations.

Clinical Landscape

Noteworthy Related Trials

2013

Hung et al. Hyperimmune IVIG Trial

n = 35 · Chest

Tested

H1N1-specific hyperimmune IVIG

Population

Patients with severe pandemic influenza A(H1N1) infection

Comparator

Normal IVIG

Endpoint

Viral load reduction and mortality

Key result: Treatment with H1N1-specific hyperimmune IVIG significantly reduced viral load and mortality compared to standard IVIG.

2018

CAPSTONE-2 Trial

n = 2184 · NEJM

Tested

Baloxavir marboxil single dose

Population

Outpatients with influenza at high risk for complications

Comparator

Placebo and Oseltamivir

Endpoint

Time to improvement of influenza symptoms

Key result: Baloxavir was superior to placebo in reducing symptom duration and superior to both placebo and oseltamivir in rapidly reducing viral load.

2019

INSIGHT 005 Trial

n = 28 · Lancet Respir Med

Tested

Anti-influenza immune plasma

Population

Adults hospitalized with severe influenza A

Comparator

Non-immune plasma (Placebo)

Endpoint

Clinical status on day 7

Key result: The study was halted early due to slow recruitment but demonstrated that passive immunotherapy administration was safe and feasible in severe influenza.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis